Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CollaSeal (also known as the T-CD patch) is a sponge-like, collagen-based hemostatic wound dressing that incorporates thrombin and L-3,4-dihydroxyphenylalanine (L-DOPA/levodopa). Developed and manufactured by Dalim Tissen, it is used clinically to prevent postoperative pancreatic fistula (POPF) and postpancreatectomy hemorrhage (PPH) in patients undergoing pancreatic resection. The thrombin component acts as a serine protease to catalyze the conversion of fibrinogen into fibrin, promoting rapid blood coagulation. The L-DOPA component provides unique adhesive properties, inspired by mussel proteins, which facilitate the patch's secure attachment to wet tissue surfaces at the surgical site. The collagen matrix serves as a structural scaffold and further contributes to hemostasis by promoting platelet activation. The patch features a porous honeycomb structure designed to optimize the absorption of blood and surgical exudates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thrombin + levodopa.